News 2017-03-17
Porton Completes Move to New Headquarters.
Mar 17, 2017, Chongqing, China: Porton Fine Chemicals is pleased to announce the relocation of its global headquarters and Chongqing Process R&D Center to a state of the art facility located in Shuitu High-Tech Park near Chongqing International Airport, China. Located on a beautiful 20 km2 campus, Porton’s Shuitu Headquarters offers 4,800 m2 of state of the art office and conference space, and hosts all centralized corporate and back-office functions to seamlessly support our sites in China, Europe and the United States.
Porton’s Shuitu campus also features our new state of the art Chongqing Process R&D Center. Featuring 4,800 m2 of R&D space including process laboratories, analytical chemistry zone, kilo-laboratory assets, hydrogenation and process safety laboratories, our Shuitu Process R&D Center brings the collective expertise and experience of >100 process chemists and analytical scientists. We are truly excited about applying this world-class facility’s capabilities to deliver compelling, cross life-cycle chemical process innovation solutions to our valued global pharmaceutical industry customers. Contact us today to attend our Open House on June 25th, 2017 or to schedule a private tour at your convenience.
Others
More
News 2025-04-16
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).

News 2025-04-11
Porton Newsletter - March 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities